Investments
43Portfolio Exits
24About Merlin Biomed Group
Merlin BioMed Group is a Registered Investment Advisor which invests globally in public healthcare companies. Founded in January, 1998, by Dr. Stuart T. Weisbrod, Merlin BioMed Group and its affiliates encompass several hedge funds. Currently, the Merlin BioMed Group investment team consists of 5 investment professionals, including 2 MDs and 1 Ph.D. All draw on their varied healthcare backgrounds and experience to provide our firm with deep and broad industry knowledge spanning later stage biotechnology, pharmaceuticals, medical devices and healthcare services. Our investor base consists of institutions, pension funds, endowments, funds of funds, family offices and high net worth individuals.
Want to inform investors similar to Merlin Biomed Group about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Merlin Biomed Group
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Merlin Biomed Group in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Merlin Biomed Group Investments
43 Investments
Merlin Biomed Group has made 43 investments. Their latest investment was in Gemin X as part of their Series C on June 6, 2008.
Merlin Biomed Group Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/13/2008 | Series C | Gemin X | $38M | Yes | BDC Healthcare Venture Fund, Canadian Medical Discoveries Fund, Caxton Advantage Life Sciences Fund, Caxton Global, CDP/Vantage Point, Fonds de Solidarite FTQ, H.I.G. BioHealth Partners, HBM Healthcare Investments, Merlin Biomed Group, Ontario Teachers', Pinnacle Bioventures, ProQuest Investments, Sanderling Ventures, and Softbank Capital | |
10/5/2007 | Series E - II | Xencor | $15M | Yes | 1 | |
6/8/2007 | PIPE - IV | Targeted Genetics | $19.46M | Yes | ||
5/4/2007 | Series D | |||||
1/24/2007 | Unattributed VC |
Date | 6/13/2008 | 10/5/2007 | 6/8/2007 | 5/4/2007 | 1/24/2007 |
|---|---|---|---|---|---|
Round | Series C | Series E - II | PIPE - IV | Series D | Unattributed VC |
Company | Gemin X | Xencor | Targeted Genetics | ||
Amount | $38M | $15M | $19.46M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | BDC Healthcare Venture Fund, Canadian Medical Discoveries Fund, Caxton Advantage Life Sciences Fund, Caxton Global, CDP/Vantage Point, Fonds de Solidarite FTQ, H.I.G. BioHealth Partners, HBM Healthcare Investments, Merlin Biomed Group, Ontario Teachers', Pinnacle Bioventures, ProQuest Investments, Sanderling Ventures, and Softbank Capital | ||||
Sources | 1 |
Merlin Biomed Group Portfolio Exits
24 Portfolio Exits
Merlin Biomed Group has 24 portfolio exits. Their latest portfolio exit was Cepheid on November 05, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/5/2016 | Acq - P2P | 2 | |||
1/11/2015 | Acq - P2P | 1 | |||
12/8/2014 | Acquired | 1 | |||
Date | 11/5/2016 | 1/11/2015 | 12/8/2014 | ||
|---|---|---|---|---|---|
Exit | Acq - P2P | Acq - P2P | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 | 1 | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
